Besides OptuneTM, the other type of treatment approved by the FDA and recommended as a standard in National Comprehensive Cancer Network guidelines for recurrent GBM is the anti-vascular endothelial growth factor (VEGF) monoclonal antibody, Bevacizumab (16, 17). This evidence concerns the gene VEGFA and glioblastoma.